Cardiovascular (heart) disease is one of Neuland’s core therapeutic areas, with multiple Neuland products in the space. It’s also the leading cause of death worldwide, and (sadly…for the sake of…
Reducing Mutagens, Carcinogens & Other Genotoxins to Improve Safety Profiles There are a number of process modifications API manufacturers can make to improve safety profiles, reduce production costs, improve capacity…
I’ve written before about aspects of Neuland’s corporate culture that directly affect our clients, such as our quality focus and our environmental waste mitigation of processing chemicals. I’ve also dropped…
There have been some tremendous gains made in the pharma industry’s understanding of Active Pharmaceutical Ingredient (API) design, and it’s reflected in the APIs currently in development around the globe….
Environmental protection and the prevention of occupational illness and work injuries are key pillars of corporate responsibility and stewardship. But Environment, Health and Safety (EHS) isn’t a break-down-the-doors kind of topic….
Active Pharmaceutical Ingredients (APIs, or – in layman’s terms – the ingredients that makes drugs work) have grown increasingly complex. Today’s equivalent of boiling tree bark into a tincture typically…
Last week, we wrote a post on new analytical methods for the detection of impurities that our R&D group had developed for the drug Febuxostat. And we’ve done the same…
In this month’s issue of PharmTech, team members at Neuland’s R&D Center in Hyderabad published a peer-reviewed article on the analysis and management of impurities in the drug Febuxostat. Febuxostat, a…
I hope everyone had a great summer! We’ve certainly kept busy. We started July with our rebranding, and spent the summer manufacturing plenty of APIs, drugs and peptides. And while…
Hitting a milestone such as 30 years old as a pharmaceutical manufacturing company is a pretty big deal. Pharma – as you can imagine – has changed. A lot. Thirty…
